Special Issue

Chemotherapy and Hematopoietic Stem Cell Transplantation

Message from the Guest Editor

Chemotherapy and hematopoietic transplantation have revolutionized the treatment of hematologic malignancies and other life-threatening disorders, offering curative potential for many patients. The advent of personalized medicine has further transformed this field by tailoring treatments to the genetic, molecular, and immunologic profiles of individual patients, thereby optimizing efficacy while minimizing toxicity.

This Special Issue aims to explore recent innovations in chemotherapy and hematopoietic transplantation, with a particular emphasis on how personalized medicine is shaping these fields. Topics will include novel agents, conditioning strategies, and emerging cellular therapies, all within the context of tailoring treatments to individual patient characteristics.

We welcome studies that highlight personalized approaches to reduced-toxicity conditioning, targeted therapies, graft-versus-host disease prevention, and the integration of gene editing and immunotherapy into transplantation. Particular interest will be given to research that demonstrates how molecular and genomic insights are being translated into clinical practice.

Guest Editor

Dr. Luisa Sisinni

Pediatric Hematology-Oncology Department, La Paz University Hospital, 28046 Madrid, Spain

Deadline for manuscript submissions

15 November 2025

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/231063

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

MDPI

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI